Pharma Mar SA ( (ES:PHM) ) has provided an announcement.
Pharma Mar S.A. has announced a share buy-back program authorized by its General Shareholders’ Meeting, aiming to reduce the company’s share capital and enhance earnings per share. The program, managed by JB CAPITAL MARKETS, S.V., S.A.U., will involve purchasing up to 91,111 shares at a maximum monetary amount of €9,000,000, with operations commencing on March 3, 2025, and potentially running until February 28, 2026. This strategic move is intended to improve shareholder remuneration and is aligned with regulatory standards for market abuse and stabilization measures.
More about Pharma Mar SA
Pharma Mar S.A. is a company operating in the pharmaceutical industry, focusing on the development and commercialization of marine-derived drugs. Its primary market focus is on oncology, leveraging its expertise in marine biotechnology to create innovative cancer treatments.
YTD Price Performance: 24.27%
Average Trading Volume: 1,486
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.82B
For a thorough assessment of PHM stock, go to TipRanks’ Stock Analysis page.